Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND

被引：0

作者：

Simpson, Eric ^{[1
]}

Paller, Amy ^{[2
]}

Wollenberg, Andreas ^{[3
]}

Bewley, Anthony ^{[4
]}

Cork, Michael ^{[5
,6
]}

Hong, Chih-Ho ^{[7
]}

Soong, Weily ^{[8
]}

Almgren, Peter ^{[9
]}

Carlsson, Anna ^{[9
]}

Blauvelt, Andrew ^{[10
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA

[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

[3] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergy, Munich, Germany

[4] Barts Hlth NHS Trust, London, England

[5] Univ Sheffield, Sheffield Dermatol Res, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England

[6] Sheffield Teaching Hosp, NIHR Clin Res Facil, Sheffield, S Yorkshire, England

[7] Univ British Columbia, Vancouver, BC, Canada

[8] AllerVie Hlth, Alabama Allergy & Asthma Ctr, Birmingham, AL USA

[9] LEO Pharma AS, Ballerup, Denmark

[10] Oregon Med Res Ctr, Portland, OR USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：AB190 / AB190

页数：1

共 50 条

[1] LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Wollenberg, Andreas
Paller, Amy S.
Bewley, Anthony
Cork, Michael
Hong, Chih-Ho
Soong, Weily
Oland, Christian Bjerregard
Taveira, Christian Moreira
Gjerum, Le
Blauvelt, Andrew
[J]. ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 54 - 54
[2] Long-term improvements observed in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: an ECZTEND interim analysis
Blauvelt, A.
Lacour, J. -P.
Toth, D.
Laquer, V.
Beissert, S.
Wollenberg, A.
Herranz, P.
Pink, A.
Peris, K.
Fangel, S.
Saeki, H.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E112 - E113
[3] Long-Term Improvement in Patients with moderate to severe atopic Dermatitis treated with Tralokinumab: An ECZTEND Interim Analysis
Beissert, Stefan
Blauvelt, Andrew
Lacour, Jean-Philippe
Toth, Darryl
Laquer, Vivian
Herranz, Pedro
Pink, Andrew
Peris, Ketty
Fangel, Stine
Saeki, Hidehisa
Wollenberg, Andreas
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 29 - 30
[4] Long-term safety and efficacy of tralokinumab in more than 1400 moderate-to-severe atopic dermatitis patients treated for up to 42 months: An interim analysis of ECZTEND
Blauvelt, Andrew
Langley, Richard
Simpson, Eric
Warren, Richard B.
Costanzo, Antonio
Saeki, Hidehisa
Toth, Darryl
Tauber, Marie
Pinter, Andreas
Ameen, Mahreen
Reich, Kristian
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB181 - AB181
[5] Long-term safety and efficacy of tralokinumab in more than 1400 patients with moderate-to-severe atopic dermatitis treated for up to 42 months: an interim analysis of ECZTEND
Blauvelt, Andrew
Langley, Richard
Simpson, Eric
Warren, Richard B.
Costanzo, Antonio
Saeki, Hidehisa
Fangel, Stine
Lassota, Nathan
Carlsson, Anna
Toth, Darryl
Tauber, Marie
Pinter, Andreas
Ameen, Mahreen
Reich, Kristian
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E92 - E93
[6] Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
Blauvelt, Andrew
Langley, Richard G.
Lacour, Jean-Philippe
Toth, Darryl
Laquer, Vivian
Beissert, Stefan
Wollenberg, Andreas
Herranz, Pedro
Pink, Andrew E.
Peris, Ketty
Fangel, Stine
Gjerum, Le
Corriveau, Joshua
Saeki, Hidehisa
Warren, Richard B.
Simpson, Eric
Reich, Kristian
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 815 - 824
[7] Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial
Blauvelt, Andrew
Lacour, Jean-Philippe
Toth, Darryl
Laquer, Vivian
Beissert, Stefan
Wollenberg, Andreas
Herranz, Pedro
Pink, Andrew
Peris, Ketty
Saeki, Hidehisa
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB159 - AB159
[8] Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis
Merola, Joseph F.
Butler, Daniel C.
Mark, Thomas
Schneider, Shannon
Kim, Yestle
Abuabara, Katrina
[J]. JAMA DERMATOLOGY, 2023, 159 (10) : 1119 - 1123
[9] Long-Term Safety, Efficacy, and Adherence of Tralokinumab for the Treatment of Patients with moderate to severe atopic Dermatitis over a Period of up to 3 Years: Interim Analysis of ECZTEND, a Phase III Long-Term Extension Study
Wollenberg, Andreas
Blauvelt, Andrew
Lacour, Jean-Philippe
Toth, Darryl
Laquer, Vivian
Herranz, Pedro
Pink, Andrew
Peris, Ketty
Saeki, Hidehisa
Beissert, Stefan
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 19 - 20
[10] Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis
Blauvelt, Andrew
Hong, H. Chih-ho
Peris, Ketty
Katoh, Norito
Tauber, Marie
Ameen, Mahreen
Gooderham, Melinda
Oland, Christian Bjerregard
Tindberg, Ann-Marie
Gjerum, Le
Reich, Kristian
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 30 - 31

← 1 2 3 4 5 →